Otamixaban

Otamixaban

SCHEMBL12589586

COC(=O)C(Cc1cccc(C(=N)N)c1)C(C)NC(=O)c1ccc(-c2cc[n+]([O-])cc2)cc1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

F10

The experimentally established mechanism targets of Otamixaban. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 5)

geneUniProtsupporting neighboursconfidence
F10 known ✓ P00742 20/20 1.00
PRSS1 P07477 18/20 1.00
TMPRSS2 O15393 1/20 1.00
F2 P00734 5/20 0.81
PLG P00747 1/20 0.77

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Otamixaban SCHEMBL12447697 1.00 F10 (1.00) F10PRSS1TMPRSS2F2PLG
Otamixaban SCHEMBL29426323 1.00 F10 (1.00) F10PRSS1TMPRSS2F2PLG
Otamixaban SCHEMBL52983 1.00 F10 (1.00) F10PRSS1TMPRSS2F2PLG
Otamixaban SCHEMBL16588897 0.99 F10 (0.98) F10PRSS1TMPRSS2F2PLG
Otamixaban SCHEMBL7890763 0.99 F10 (0.98) F10PRSS1TMPRSS2F2PLG
SCHEMBL12805269 0.93 F10 (0.86) F10PRSS1TMPRSS2F2PLG
SCHEMBL15489295 0.92 F10 (1.00) F10PRSS1TMPRSS2F2PLG
SCHEMBL14542917 0.92 F10 (0.86) F10PRSS1TMPRSS2F2PLG
SCHEMBL13160832 0.92 F10 (1.00) F10PRSS1TMPRSS2F2PLG
SCHEMBL19222680 0.92 F10 (0.86) F10PRSS1TMPRSS2F2PLG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7970581-B2 Methods of calculating differences of binding affinities between congeneric pairs of ligands by way of a displaced solvent functional THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) 2011-06-28 US disclosed
US-7970580-B2 Methods of calculating differences of binding affinities between congeneric pairs of ligands by way of a displaced solvent functional THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) 2011-06-28 US disclosed
US-20100241411-A1 Methods of Calculating Differences of Binding Affinities Between Congeneric Pairs of Ligands by Way of a Displaced Solvent Functional NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2010-09-23 US disclosed
US-7756674-B2 Methods of calculating differences of binding affinities between congeneric pairs of ligands by way of a displaced solvent functional THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) 2010-07-13 US disclosed
US-20090037136-A1 Methods of calculating differences of binding affinities between congeneric pairs of ligands by way of a displaced solvent functional NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2009-02-05 US disclosed
US-20070111947-A1 Fibrin targeted therapeutics MCMURRY THOMAS J 2007-05-17 US disclosed
WO-2007047608-A2 FIBRIN TARGETED THERAPEUTICS EPIX PHARMACEUTICALS, INC. (US) 2007-04-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070111947-A1 Fibrin targeted therapeutics FGB, F13B, F2 F10 15/4885PRSS1 170/4885TMPRSS2 89/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.